Alzheimer's disease is the most common form of age-related neurodegenerative dementia. The disease is characterised by the presence of plaques in the cerebral cortex. The major constituent of these plaques is aggregated amyloid-b peptide. This review focuses on the molecular aspects of metal complexes designed to bind to amyloid-b. The development of radioactive metal-based complexes of copper and technetium designed as diagnostic imaging agents to detect amyloid burden in the brain is discussed.
Brief introduction to the pathology of Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative condition that results in synaptic failure and neuronal death. These symptoms initially manifest as mild forgetfulness but lead to complete loss of cognition. 1 Characteristic pathological hallmarks in the brains of those suffering with the disease include the presence of extracellular senile plaques, intracellular neurofibrillary tangles and altered levels of neurotransmitters. Amyloid plaques are composed of an insoluble aggregated peptide called amyloid-b (Ab). 2, 3 This peptide is 39-43 residues in length and derived from the amyloid-b precursor protein (APP). The amyloid plaque burden in subjects does not consistently correlate with cognitive impairment and some argue that smaller soluble oligomeric species are the toxic species responsible for neuronal death. [4] [5] [6] [7] [8] However, oligomers and plaques are thought to be in equilibrium. Although the exact role of amyloid plaques in the onset of dementia is controversial, what is certain is that histopathological studies show extensive cortical Ab deposition in post-mortem analysis of AD subjects. 1 Neurofibrillary Tangles (NFT) consist of a hyper phosphorylated form of a microtubuleassociated protein called tau. NFT initiate with the formation of bundles of paired helical filaments that accumulate in the neuronal cytoplasm. The hyper-phosphorylation of tau results in its detachment from microtubules that consequently lose structural integrity with concomitant impaired axonal transport and compromised synaptic function. 9 Another prominent and consistent feature of AD is deficits to the acetylcholine (cholinergic) neurotransmitter system. Post-mortem studies have revealed cholinergic neuronal loss and reduced acetylcholine levels. This correlates with a decrease in the concentration of acetylcholine esterase, an enzyme responsible for the hydrolysis of acetylcholine in the brain. 10 The focus of this review is metal complexes designed to bind to either Ab fibrils or Ab plaques as distinct from metal-binding ''free'' ligands designed to displace either copper or zinc or iron ions that are thought to be bound to Ab plaques. The approaches that are discussed in this review include: the potential of radioactive copper and technetium complexes to be used as diagnostic imaging agents to elucidate plaque burden in living patients; the use of luminescent metal complexes as non-conventional probes of amyloid formation; and the use of platinum, ruthenium, iridium and rhodium metal complexes to inhibit the aggregation and toxicity of Ab. Several elegant and sophisticated approaches that use chelating ligands designed to attenuate Cu II /Zn II -Ab interactions and redistribute metal ions bound to Ab plaques that are of significant interest as potential therapeutics will not be discussed in this review but selected leading references [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and reviews [27] [28] [29] [30] [31] [32] are available.
The amyloid-b peptide and plaques
The amyloid precursor protein (APP) is encoded by a single gene on chromosome 21 and resembles a cell-surface receptor having a single transmembrane domain, a large extracellular domain and a short cytoplasmic tail. The transmembrane domain extends 1, 36, 37 Amyloid is a general term used to describe peptides or proteins that form b-sheets which accumulate as highly ordered fibrillar aggregates. 40 One of the earliest methods to identify amyloids was the apple green birefringence histological dye Congo Red (Fig. 5 ) displayed once bound to amyloid when observed under polarized light leading to the first definition criterion of amyloid. [41] [42] [43] The second definition criterion for amyloid is to possess fibrillar morphology. 43, 44 Negatively stained thin tissue sections containing amyloid imaged with electron microscopy (EM) reveal bundles of straight, rigid fibrils. Mature amyloid fibrils are estimated to be about 75-100 Å in width. Assembly involves two to four thin protofilaments twisting together parallel to the fibril axis. An individual protofilament consists of several b-sheets composed of peptide chains bound together by hydrogen bonds. The b-strands (monomeric Ab) are aligned perpendicular to the fibril axis (cross-b structure) (Fig. 2) . 45, 46 Electron microscopy and X-ray diffraction analysis of the Ab protofilament reveals the inter-peptide chain spacing to be about 4.8 Å and inter-sheet spacing to be about 10 Å, characteristic of the cross-b structure. 42, 47, 48 Amyloid fibrils are not crystalline and generally insoluble in aqueous solvents. This precludes analysis by conventional solution NMR. Nevertheless, recent advances in cryoelectron microscopy and solid-state NMR have provided structural information on the inter-and intra-molecular interactions that bind the cross-b structural motifs of Ab fibrils. 45, [48] [49] [50] [51] [52] [53] Structural studies using fibrils formed from 35Mox Ab 42 peptides (containing a methionine sulfoxide at position 35) have given insight into the 3D structure of Ab 42 fibrils (Fig. 3) . The methionine is oxidised during the production of the monomeric peptide but maintains similar properties to the non-oxidised Ab 42 . 54 A single 35Mox Ab 42 protofilament consists of two b-sheets (b1 and b2) that run along the fibril axis forming a parallel b-sandwich stabilized by inter-bsheet side-chain interactions. Residues 17-26 define sheet b1 and residues 31-42 form sheet b2 with a connecting loop containing residues 27-30. Intermolecular interactions between amino acid residues on b1-and b2-sheets involve ionic interactions (Asp23 and Lys28), hydrophobic interactions (Leu17, Phe19, Ala21, Gly38 and Val36) and backbone hydrogen bonds. The loop region and b1 interact by salt bridge formation between the side-chains of residues Asp23 and Lys28. Residue Lys28 also forms close contacts with residues Ile32 and Leu34 of b2. The intermolecular hydrophobic interaction formed between the odd-numbered residues of the b1-strands (Leu17, Phe19 and Ala21) and the even-numbered residues (Gly38 and Val36) of neighbouring b2-strands establishes the hydrophobic core of Ab 42 fibrils. The extension and growth of the Ab 42 protofilament is unidirectional; an incoming nth Ab 42 monomer can initiate contact with the fibrillar end by means of hydrophobic interactions between its b1-strand and the b2-strand of the (n À 1)th monomer. The ionic interactions between the residues in the loop regions and backbone hydrogen bonds further strengthen the intermolecular association. In order to prevent the dissociation of the nth monomer, another Ab 42 monomer is required to interact with the b2-strand of the nth monomer to stabilize it. This suggests that the sequence-selective and cooperative mechanism of Ab 42 fibril growth is a first-order kinetic process. 46 
Structural morphology of amyloid plaques
The relationship between soluble Ab monomers, oligomers Ab, protofibrils, fibrils and plaques is complicated and several aspects of the dynamics remain uncertain. 55, 56 Amyloid-b plaques are classified into two morphological types: (i) neuritic and (ii) diffuse (''pre-amyloid'') plaques (Fig. 4) . Neuritic plaques, observed after staining, have a dense compact spherical appearance with a diameter ranging from 10 mm to greater than 120 mm. Neuritic plaques can be further sub-classified into 'fibrillar' or 'dense-cored' plaque forms. Fibrillar plaques show dense accumulations of Ab throughout the plaque structure (Fig. 4B ) whereas cored plaques have a distinct central core of Ab encircled by a void or clearing surrounded by an outer spherical rim of Ab (Fig. 4A ). These Ab deposits are referred to as neuritic plaques as they are spatially localized with dystrophic neuritis (clusters of abnormal neuronal processes) both inside and immediately surrounding the deposits. [57] [58] [59] Following staining, diffuse plaques display a finely granular pattern of amorphous shape that lacks a fibrillar, compacted centre (Fig. 4C ). These non-fibrillar plaques are the only Ab deposits found in regions of the brain not clearly associated with the typical symptoms of AD. They also form within the same regions of the brain as neuritic plaques, however, very little or no detectable dystrophic neurites are associated with diffuse plaques. Studies in a transgenic AD mouse model, expressing mutant human APP, show that the mice develop diffuse plaques before fibrillar plaques supporting the hypothesis that diffuse plaques are immature or precursor lesions to neuritic plaques and are therefore also termed ''pre-amyloid'' plaques. 57 
Molecules that bind to Ab fibrils and plaques
The histopathological dyes Congo Red and Thioflavin T (ThT) (Fig. 5 ) have provided the structural inspiration for the development of many radiolabeled tracers aimed at detection of amyloid in living patients. Both dyes are relatively planar, hydrophobic aromatic molecules that interact with and bind to the cross-b sheet structure found in all amyloid fibrils. They are unable to cross the blood-brain barrier at least in part due to their ionic charge.
Over the last decade there has been significant progress in the development of positron emission tomography (PET) imaging agents to characterise Ab plaque burden. PET is a non-invasive molecular imaging technique that relies on the detection of radioactivity emitted from a positron-emitting isotope that is incorporated into a molecular tracer or imaging agent. The emitted positron annihilates releasing two gamma photons travelling in opposite directions. Detection of the emitted photons allows the generation of an image with a spatial resolution of 3-5 mm with high sensitivity. An analogue of ThT, the 2-phenylbenzothiazole derivative 2-(4(methylamino)phenyl)benzothiazol-6-ol ( 11 C-PiB) ( Fig. 6 ), contains the positron emitting isotope carbon-11, is able to cross the blood brain barrier, and labels Ab plaques in vivo. It has been used in pioneering clinical studies that have demonstrated the tremendous potential of PET imaging in assisting AD diagnosis. 60 The longer half-life of fluorine-18 when compared to carbon-11 is more practical and fluorine-18 is currently the most widely used radionuclide for PET imaging. Benzothiazole derivatives and an aromatic fluoro-substituted pyridinyl benzofuran radiolabeled with fluorine-18 are in the late stages of clinical development. The pyridinyl benzofuran compound, AZD4694 ( Fig. 6 ), has completed phase III clinical trials and compares favourably to PiB displaying relatively low non-specific binding when compared to other 18 F radiotracers. 61 Flutemetamol (Fig. 6 ), a benzothiazole derivative, has recently gained FDA approval to estimate beta amyloid neuritic plaque density.
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Another pharmacophore that has shown considerable potential in binding to Ab plaques contain diaryl alkenes such as stilbenes and styrylpyridines. The development of the 18 F labelled stilbenes and styrylpyridines is presented in a 'perspective' article 63 and the research in this area has led to the recent FDA approval of 18 F-AV45 (florbetapir) (Fig. 6 ) to detect the presence of amyloid. 64 The use of the benzothiazole dye ThT as a fluorescent probe for the detection of amyloid-like structures was first reported in 1959. 65 In protic solvents ThT absorbs at a wavelength of 340 nm with a relatively weak emission at 445 nm but when bound to amyloid fibrils the dye undergoes a 115 nm red shift in excitation profile (l ex = 445 nm) with enhanced emission at a wavelength of 485 nm. In aqueous solutions rapid rotation about the C-C bond linking the benzothiazole group to the N,N-dimethylaniline portion of the molecule provides a pathway for non-emissive decay of the excited state. This occurs by a twisted internal charged-transfer process (TICT) from a locally excited state (LE) by increasing the torsion angle from 371 to 901. The interaction of ThT with amyloid fibrils restricts rotation about the C-C bond and is partially responsible for the increased emission ( Fig. 7) . [66] [67] [68] [69] [70] It is likely that there are three different binding sites for ThT on Ab 40/42 fibrils. 71, 72 The first and second binding sites (BS1 and BS2) have higher binding affinities than the third (BS3) and are located closely and/or overlapping to each other. BS1 occurs every B35 Ab 40 monomers while BS2 occurs every B4 Ab 40 monomers and low capacity BS3 occurs every B300 Ab 40 monomers. 72 Hydrophobic grooves are formed on the b-sheet surface by the side-chains of amino acids, particularly Phe and Val. These hydrophobic grooves propagate along the ''twisting'' Ab fibril forming BS1 and BS2. Interaction of ThT with the side-chains of these grooves is thought to be primarily via p-p stacking. The low affinity and less abundant BS3 is present on the b-sheet extremities of the fibril. 73 Simulated molecular dynamics support the proposed groove binding of histological dyes and small-molecule imaging agents to amyloid. The Asp-Phe-Gly-Ala-Ile-Leu-Ser peptide sequence, found within human islet amyloid polypeptide, acts as a useful model for binding simulations of small molecule imaging agents and dyes, including ThT and the related radiotracer acid side chains decorate the large faces of the fibril to form grooves on both faces (Fig. 8a) . The top face of the fibril has a central groove consisting of isoleucine residues and two neighbouring minor grooves formed with isoleucine on one side and alternating arginine and serine residues on the other. Although the bottom face of the fibril has potential for two grooves, phenylalanine residues leaning toward the alanine residues restrict access to one groove but the small alanine residues allow room for a single small hydrophobic central groove. Amongst the multiple potential binding sites available, the two binding modes with the highest binding affinities are in the hydrophobic grooves of the top and bottom faces. The absolute energetic contributions of binding can be classified as polar or non-polar. The non-polar interactions provided the largest contributions to the interactions and a major proportion can be speculatively assigned to p-p interactions. Comparison of the charged ThT and its neutral analogue PiB reveals greater insertion into the hydrophobic grooves for PiB corresponding to a more energetically favourable binding to the fibril (Fig. 8b and c) . It is reasonable to expect this to translate to fibrils formed with other peptides, such as Ab, due to the similarity across amyloid fibril structure. 55 
Toward diagnostic imaging of Alzheimer's disease with copper radiopharmaceuticals
The positron-emitting isotopes of copper offer considerable potential for diagnostic PET imaging. 74, 75 There are two comparatively short-lived isotopes, copper-60 (t 1/2 = 20 min) which is relatively easy to produce with a small medical cyclotron and copper-62 (t 1/2 = 20 min), available from a convenient generator. Two longer half-life isotopes, copper-61 (t 1/2 = 3.4 h) and copper-64 (t 1/2 = 12.7 h) can both be produced in low energy hospital cyclotrons. 74 The low energy of the positron-emission from copper-64 is coupled to a lack of interfering gamma emissions so high quality images are obtained that are comparable to those obtained with fluorine-18. 76 In principle, the rapid and simple incorporation of a radioactive copper isotope into a specifically designed targeting ligand is an attractive alternative to the sometimes challenging covalent incorporation of carbon-11 or fluorine-18 into plaque binding tracers. Such a system needs to be carefully designed as factors such as complexation kinetics, thermodynamic stability and biodistribution need to be considered. A single ligand framework is suitable for the full range of copper isotopes and would serve as a valuable platform to develop versatile Ab plaque imaging agents and improve the ], interacts with synthetic Ab 42 fibrils in vitro and binds selectively to Ab plaques in post-mortem samples of human brains from AD subjects (Fig. 10) ] bind to Ab plaques in AD affected human brain tissue, with plaques identified by staining the contiguous section with 1E8 antibody (Fig. 11c) forming an intramolecular hydrogen bond and may alter the solvation properties of the complex thus modifying membrane permeability. It is also possible that this functional group produces other complicating interactions such as those with serum proteins or the p-glycoprotein efflux system. Further studies on these systems are warranted including investigation in transgenic models of amyloid and more detailed characterisation of their biodistribution and metabolism. 89 Specifically designed ligands to probe Ab plaque burden such as the systems presented above could be incorporated into 'kit' formulations in a similar manner to successful technetium-99m based radiopharmaceuticals. In principle, these ligands would be for suitable each of the positron-emitting isotopes of copper offering incredible versatility and flexibility from a single platform.
Technetium-99m radiotracers designed to bind to amyloid-b
Although the use of the imaging technique single photon emission computed tomography (SPECT) is routine and widespread, progress toward a SPECT compatible molecular probe has been slower than that of PET. 90 The most commonly used radioisotope for SPECT imaging is technetium-99m. This g-emitting isotope has a half-life of six hours and is available from convenient generator systems. A 99m Tc-based radiotracer for determining plaque burden would be of considerable clinical utility and increase the number of centres that are able to perform diagnostic scans for AD based on both cost and availability of the necessary infrastructure. As there are no non-radioactive isotopes of technetium, it is common practice to use the relatively stable isotopes of rhenium to form analogues of 99m Tc complexes for comprehensive characterisation and preliminary in vitro assessment. [90] [91] [92] Detailed reviews on the chemistry of technetium are available [93] [94] [95] and earlier detailed reviews on diagnostic imaging of AD with 99m Tc complexes were published in 2011 and early 2012 (see Fig. 12 for selected examples). 90 In an alternative approach a dibenzylideneacetone derivative, containing a dimethylamino group, was conjugated to both BAT and MAMA (Fig. 14) . Once again, rhenium complexes were used as non-radioactive surrogates to assess the binding affinity of complexes toward aggregated Ab. The binding affinities of MAMA rhenium complexes, [ReOL [8] [9] ], to Ab 42 aggregates were moderate (K i = 121 and 60 nm for [ReOL [8] [9] ] respectively) increasing to high affinity for BAT rhenium complexes (K i = 25 and 14 nm for [ReOL [10] [11] ] respectively). All complexes, [ReOL whereby the binding motif forms part of the chelate backbone, reduces the molecular weight of compounds and potentially aid blood-brain barrier permeability. Examples of such ligands have been synthesised incorporating 2-arylbenzothiazole (2-ABT) derivatives as the targeting motif (Fig. 15) . The binding affinity of rhenium complexes, [ReOL [12] [13] [14] [15] [16] [17] [18] [19] ], was assessed according to their binding affinity to Ab 40 fibrils and logP C18 (P C18 = estimation of P by a reverse phase HPLC method). This revealed that both the type of chelator and substitution positions about 2-ABT (see Fig. 15 ThT for numbering) influences the affinity of complexes toward Ab fibrils. ). Rhenium complexes were synthesised by acetylation of (cyclopentadienyl)tricarbonylrhenium using acetyl chloride. 91 The product was then reacted via base catalysed Claisen condensation with the chosen aromatic aldehyde enabling variation in the length of the alkenyl group within complexes (Fig. 17) . 
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A mixed ligand system, whereby bidentate and monodentate ligands are used to complete the coordination sphere about Tc). The remaining aqua ligand can be exchanged for imidazole, isocyanocyclohexane, and triphenylphosphine (Fig. 18) . 104 2+ (where bpy = 2,2-bipyridine and dppz = dipyridophenazine) (Fig. 19a) binds to DNA which results in an enhancement of luminescence attributed to a metal-ligand charge-transfer (MLCT) from the ruthenium atom to a primarily ligand (dppz) based p* orbital. MLCT excited state primarily localised on the phenazine nitrogen atoms. When the complex is in aqueous environments water quenches this excited state by hydrogen bonding with the phenazine nitrogen atoms but when the dppz is shielded from water the complex is luminescent. 107 In similar fashion to its interaction with DNA the interaction of [Ru(bpy) 2 
(dppz)]
2+ with Ab fibrils also results in a change in the polarity of the microenvironment resulting in enhanced luminescence (Fig. 19c) . 108 The use of a metal based luminescent probe with a long-lived excited state has potential advantages over more conventional dyes such as ThT. . Computational methods that combines molecular docking and all atom molecular dynamics simulation predicted that a hydrophobic cleft between Val18 and Phe20 was a likely binding site with the side chains of these two amino acid residues interacting with the dppz functional group via CH-p and p-p interactions (Fig. 19b) . 109 The versatility and potential of this family of ruthenium complexes as unconventional probes of protein aggregation is highlighted by the use of the 1,10-phenanthroline analogue, [Ru(phen) 2 Each of these platinum(II) complexes are likely to have poor bioavailability and blood-brain barrier penetration and this has the potential to compromise their clinical development for the treatment of neurodegeneration. The desire to provide orally bioavailable platinum(II) complexes with the potential to alter Ab aggregation led to the synthesis of a platinum(IV) complex with a specifically designed benzoimidazole quinoline ligand (L 25 ) (Fig. 21) . The idea of using a Pt IV complex as a pro-drug activated by in vivo reduction to a Pt II species was inspired by the similar approach used to make orally bio-available and less toxic platinum complexes for the treatment of cancer (Satraplatin attributed to the three histidine residues and tyrosine-10 implicating the histidine residues in coordination to the Ru II . 127 A ruthenium(III) monoanionic complex with two 2-aminothiazole N-bound ligands and four chloride ligands (PMRU20) (Fig. 22 ) was found to offer protection against Ab induced toxicity in rat primary cortical neurons. Interestingly two other structurally related Ru III complexes, NAMI A and KP1019 (Fig. 22) , offered little to no protection. The difference in reactivity between these complexes is intriguing and warrants further investigation. 128 The reaction of selected ruthenium complexes with proteins involved in the pathology of type II diabetes (human islet amyloid polypeptide) and prion diseases (PrP ) also results in significant changes to the aggregation of the respective proteins. This further highlights the potential of coordinate bond formation with kinetically inert metal ions to act as novel inhibitors of amyloid formation.
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Conclusions
The full details of the role Ab plaques, oligomers, tau and neurofibrillary tangles play in cognitive impairment in Alzheimer's disease remains a mystery. What is known about the extracellular amyloid deposits evident in the cortex of subjects with the disease is that they contain relatively high concentrations of aggregated amyloid-b protein, a 39-43 amino acid fragment derived from the amyloid precursor protein. Our understanding of the structure and actual function of both Ab and APP remains incomplete. It is possible that there is still much to learn about the generation, clearance and toxicity of Ab as well as the molecular dynamics involving Ab monomers, oligomers and plaques. Significant progress in the last decade has led to the development of molecular tracers that can offer insight into the deposition of amyloid in the brain of living patients using non-invasive PET imaging. The results of pioneering multi-centre studies using PET tracers to detect amyloid in large patient cohorts are emerging and providing valuable insights into the relationship between amyloid and cognition. [131] [132] [133] There are several radioactive isotopes of copper that have the potential to be of use in PET imaging and technetium-99m continues to be the radioisotope of choice for SPECT imaging. In principle, ligands designed to bind to amyloid plaques and form stable copper or technetium complexes have the potential to extend the capabilities of amyloid imaging. A new ligand based on a bis(thiosemicarbazone) framework with appended plaque targeting functional group and hybrid thiosemicarbazonestyrylpyridine ligands have shown some promise as ligands for copper radiopharmaceuticals. A wide range of Tc complexes designed to bind to Ab plaques is discussed in the review. The ''piano stool'' complex, [ 99m Tc I L 21 ] (Fig. 21) , shows significant potential and warrants further investigation. Luminescent ruthenium and iridium metal complexes with long fluorescent lifetimes that undergo significant changes to their electronic spectra upon binding to Ab fibrils have potential as useful probes to gain increased insight into the molecular aspects of amyloid formation and aggregation. The interaction of the hydrophobic complex [Ru(bpy) 2 
